Non-pegylated liposomal doxorubicin (NPLD) has demonstrated antitumour activity equivalent to conventional doxorubicin and a significantly lower risk of cardiotoxicity. This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma.
Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial / DE SANCTIS, Rita; Bertuzzi, Alexia; Basso, Umberto; Comandone, Alessandro; Marchetti, Silvia; Marrari, Andrea; Colombo, Piergiuseppe; Lutman, Romano Fabio; Giordano, Laura; Santoro, Armando. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 35:1(2015), pp. 543-548.
Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial
DE SANCTIS, RITA
;
2015
Abstract
Non-pegylated liposomal doxorubicin (NPLD) has demonstrated antitumour activity equivalent to conventional doxorubicin and a significantly lower risk of cardiotoxicity. This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma.| File | Dimensione | Formato | |
|---|---|---|---|
|
DeSanctis_Tissue-sarcoma_2015.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
103.25 kB
Formato
Adobe PDF
|
103.25 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
